Watch Vesiflo’s WEBINAR

Revolutionizing Urology: How Vesiflo’s inFlow™ Voiding Prosthesis is Disrupting the Urinary Catheter Market

Everyone knows what a big issue urinary incontinence is, but imagine the opposite problem, being unable to void. When urinary retention occurs, it is considered a serious medical condition and is always at least initially treated with urinary catheterization – but no one wants to use a catheter. Vesiflo’s mission is to reinvent urinary catheters, disrupting a very large market that has seen little in the way of innovation.

Vesiflo’s inFlow™ female voiding prosthesis™ (“inFlow”) is the first medical alternative to catheters – and it is a safer, more convenient and significantly more dignified option. It eliminates tubes and bags and allows almost normal use of a toilet, a key function of daily living. The inFlow is for women whose bladder function has been impaired by life-changing neurologic conditions such as MS, spinal cord injury, spina bifida, diabetes, etc. who would otherwise have to use catheters on a life-long basis. Initial response to inFlow has been overwhelming. Users describe it as “life changing” relative to catheterization and some 1,200 urologists are already on record as wanting to prescribe. The inFlow is FDA approved and as of January is now reimbursed by Medicare.

Based on a conservative estimate of the number of device candidates and the device price paid by CMS, the inFlow’s total addressable market in the U.S. is $1.5 Billion/year. Because its users have incurable conditions and need a new device every month, the typical inFlow user generates recurring revenues of ~$6,000 annually (12 devices @ $495 each).  

The inFlow’s unique magnetic coupling is a platform technology that Vesiflo will build on. A male version of the inFlow, the IntelliFlow™ male voiding prosthesis, has completed first-in-human testing and other devices are in design stages. These new designs are expected to add to the Company’s patent portfolio, which already includes 10 U.S. patents and foreign counterparts.

Vesiflo is headed by Kevin Connolly, an industry veteran and thought leader in female urology who previously founded and operated four (4) medical device manufacturing companies. Most recently, Mr. Connolly was Founder and CEO of www.srsmedical.com, where he acquired and developed a comprehensive product line for the diagnosis and conservative treatment of incontinence and other voiding disorders, including some of the most innovative urodynamics systems in the industry.

This is a unique opportunity for the SFOG community to participate in a de-risked medtech company that is about to enter its growth phase and may be the last chance for non-institutional investors to participate in Vesiflo. We look forward to seeing you on our upcoming SFOG webinar in February.

To learn more please contact Spotlight Family Office Group at Info@SpotlightFamilyOffice.com.